Acrivon Therapeutics Reports Financial Results

Acrivon Therapeutics has released its financial results for the fourth quarter and the full year of 2025, alongside updates on its business progress. The company highlighted maturing data from its Phase 2b study for ACR-368, which targets serous endometrial cancer. This study demonstrated a confirmed overall response rate of 52%, indicating promising efficacy for the therapeutic candidate. These results are crucial for the company's ongoing development and potential future commercialization efforts in the oncology space.